# US Specialty Formulations LLC - Inspection Records

Source: https://www.keypedia.com/companies/us-specialty-formulations-llc/2a5dd57a-6a0b-44a4-88ec-d642f91d1315

> Inspection records and compliance data for US Specialty Formulations LLC in Allentown, Pennsylvania. Access full analysis and detailed observations.

---

## Details

- Name: US Specialty Formulations LLC
- FEI Number: 3010680515
- City: Allentown
- State: Pennsylvania
- Country Name: United States
- Address Line 1: 1401 S Albert St
- Zip Code: 18103

## Related Documents

- [483 - US Specialty Formulations LLC - Unknown Date](https://www.keypedia.com/records/483/us-specialty-formulations-llc/4dd416c3-7118-437a-bcb5-8ca83ae76b15) — source: FDA, date: Invalid Date
- [483 - US Specialty Formulations LLC - 2026-01-14](https://www.keypedia.com/records/483/us-specialty-formulations-llc/48b75557-852b-44d0-b313-616e9c14b667) — source: FDA, date: January 14, 2026
- [FDA Inspection 1298396 - US Specialty Formulations LLC - 2026-01-14](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/e72c419c-3eb9-4794-a8df-38ab824d37c6) — source: FDA, date: January 14, 2026
- [483 - US Specialty Formulations LLC - 2025-03-26](https://www.keypedia.com/records/483/us-specialty-formulations-llc/a05165b7-ed9d-4680-b279-3e464026ec25) — source: FDA, date: March 26, 2025
- [FDA Inspection 1265449 - US Specialty Formulations LLC - 2025-03-26](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/e25bcef3-888a-4f3e-b64b-223257e43fa2) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 26, 2025
- [483 - US Specialty Formulations LLC - 2024-07-02](https://www.keypedia.com/records/483/us-specialty-formulations-llc/02180e72-25a9-4bdf-970c-9567cf7a7ce8) — source: FDA, date: July 2, 2024
- [FDA Inspection 1243882 - US Specialty Formulations LLC - 2024-07-02](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/dd9ee101-2a34-4453-ad4e-ba79c9bf11c3) — classification: Official Action Indicated (OAI), source: FDA, date: July 2, 2024
- [483 - US Specialty Formulations LLC - 2022-04-26](https://www.keypedia.com/records/483/us-specialty-formulations-llc/2ff0d13c-a3ce-40eb-ad34-b5b1e999f613) — source: FDA, date: April 26, 2022
- [FDA Inspection 1167934 - US Specialty Formulations LLC - 2022-04-26](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/737bef48-423a-4dcc-92af-ca91074c2095) — classification: Official Action Indicated (OAI), source: FDA, date: April 26, 2022
- [FDA Inspection 1167934 - US Specialty Formulations LLC - 2022-04-26](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/c2529d65-9b9a-4df4-95ab-aed2f8190c7d) — classification: Official Action Indicated (OAI), source: FDA, date: April 26, 2022
- [FDA Inspection 1097950 - US Specialty Formulations LLC - 2019-07-23](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/d3651a69-ca0b-4e10-a392-9496baabe17c) — classification: Official Action Indicated (OAI), source: FDA, date: July 23, 2019
- [FDA Inspection 1023411 - US Specialty Formulations LLC - 2017-08-29](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/33cfa969-db8c-466f-a448-732a50bd78d8) — classification: Official Action Indicated (OAI), source: FDA, date: August 29, 2017
- [FDA Inspection 928445 - US Specialty Formulations LLC - 2015-05-29](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/5d7280bc-635f-46cf-a2e4-4cc7a960a004) — classification: Official Action Indicated (OAI), source: FDA, date: May 29, 2015
- [FDA Inspection 871574 - US Specialty Formulations LLC - 2014-03-18](https://www.keypedia.com/records/fda_inspections/us-specialty-formulations-llc/99f409a5-5f1d-436e-8b47-ab3de37814d4) — classification: No Action Indicated (NAI), source: FDA, date: March 18, 2014

## Related Companies

- [Sonneborn, LLC](https://www.keypedia.com/companies/sonneborn-llc/a3b94b8f-4ffb-4c19-9bb5-b8cfc23c7f58)
- [Exxonmobil Product Solutions Company](https://www.keypedia.com/companies/exxonmobil-product-solutions-company/8e83c4a4-cc31-4bfd-abc9-d6f2df29259f)
- [Hetero Drugs Ltd. - Unit 1](https://www.keypedia.com/companies/hetero-drugs-ltd-unit-1/4c15935a-9ff7-4f66-b649-3d78aa3e9753)
- [Smithfield Bioscience Inc](https://www.keypedia.com/companies/smithfield-bioscience-inc/f87613b8-a59a-4a6d-b412-9f2b145f397b)
- [SRI Krishna Pharmaceuticals Ltd - Unit I](https://www.keypedia.com/companies/sri-krishna-pharmaceuticals-ltd-unit-i/a8609781-dc13-4ad6-9bb3-047ead2bf151)
- [CTX Lifesciences Private Ltd.](https://www.keypedia.com/companies/ctx-lifesciences-private-ltd/cbf6df36-d316-40a9-891a-10cbbb4e757f)
- [Shenzhen Oriental Pharmaceutical Co Ltd](https://www.keypedia.com/companies/shenzhen-oriental-pharmaceutical-co-ltd/71227651-964f-4f33-a24b-5c0b0f6c92a0)
- [Zhejiang Haisen Pharmaceutical Co., Ltd.](https://www.keypedia.com/companies/zhejiang-haisen-pharmaceutical-co-ltd/2d2c27d1-770f-4367-a180-92298e925ab8)
- [Sri Krishna Pharmaceuticals Limited - Unit IV](https://www.keypedia.com/companies/sri-krishna-pharmaceuticals-limited-unit-iv/fd405e8b-b747-4adb-bbb5-da63c0cfa56b)
- [Pharmazell (India) Private Ltd](https://www.keypedia.com/companies/pharmazell-india-private-ltd/1a60e2bc-b058-468d-b52f-ba85d9f757d2)

## Related Officers

- [Vascular Neurologist Investigator](https://www.keypedia.com/people/sean-d-duke/ea627ffa-8e7c-4c2e-a9e0-31a41fe44ccf)
- [Investigator](https://www.keypedia.com/people/edmund-f-mrak/a43cf86a-c020-4948-bff6-358b2453908a)
- [Ucheabuchi C. Chudi-nwankwor](https://www.keypedia.com/people/ucheabuchi-c-chudi-nwankwor/18b01d08-3cfd-4ace-97b2-5f54b6427661)
- [Rabinah Anatullah](https://www.keypedia.com/people/rabinah-anatullah/ec3a3855-2e6c-460f-827c-16fe0f406635)
- [Investigator](https://www.keypedia.com/people/lu-chen/d0700911-c592-4da7-a445-5dfb2a4bedff)